NR 546 / NR546 MIDTERM / FINAL EXAM 2026/2027
PREDICTION 175 QUESTIONS (ALL CORRECT
ANSWERS, ALREADY GRADED A)
Advanced Pharmacology: Psychopharmacology for the Psychiatric-Mental Health Nurse Practitioner
(PMHNP)
Chamberlain University Course Alignment | Graduate Nursing and Advanced Practice
Psychiatric-Mental Health Education
All Correct Answers Marked with Detailed Rationales | Cognitive Mix: 20% Recall - 50% Application - 30% Analysis |
75% Scenario Based, 25% Direct Knowledge
Section 1: Principles of Psychopharmacology
Q1: A nursing student is reviewing the four phases of pharmacokinetics as they apply to
psychotropic medications. Which term describes the movement of a drug from the systemic
circulation into target tissues such as the brain, liver, and fat stores?
A. Absorption
B. Distribution *[CORRECT]*
C. Biotransformation
D. Excretion
Correct Answer: B
Rationale: Distribution is the movement of a drug from the bloodstream into tissues and is heavily influenced by
protein binding, lipid solubility, and regional blood flow (NR 546, Module 1: Pharmacokinetic Principles).
Absorption describes entry into the bloodstream from the administration site, while biotransformation
(metabolism) and excretion describe elimination processes. Understanding distribution is essential when
predicting central nervous system penetration of psychotropics.
Aligned with AACN Essentials of Master's Education and PMHNP Psychopharmacology Competencies 1
,NR 546 Advanced Pharmacology: Psychopharmacology - PMHNP Exam Prediction
Q2: Which statement accurately differentiates pharmacodynamics from pharmacokinetics?
A. Pharmacokinetics describes receptor binding and downstream second-messenger
activity
B. Pharmacodynamics describes the concentration of drug achieved in the cerebrospinal
fluid
C. Pharmacodynamics describes what a drug does to the body, including receptor affinity
and signal transduction *[CORRECT]*
D. Pharmacokinetics describes the relationship between dose and therapeutic response at
the receptor
Correct Answer: C
Rationale: Pharmacodynamics refers to the biochemical and physiologic effects of drugs and their mechanisms
of action, including receptor binding, enzyme inhibition, and second-messenger signaling. Pharmacokinetics, in
contrast, describes what the body does to the drug across absorption, distribution, metabolism, and excretion
(AACN Essentials, scientific foundation domain). Options A and D reverse the definitions, and option B describes
a pharmacokinetic measurement.
Q3: A newly developed antipsychotic is noted to cross the blood-brain barrier readily. Which
drug property best explains effective central nervous system penetration?
A. High ionization at physiologic pH
B. Strong binding to plasma albumin
C. High molecular weight with poor solubility
D. High lipid solubility at physiologic pH *[CORRECT]*
Correct Answer: D
Rationale: The blood-brain barrier consists of tight junctions and astrocytic foot processes that permit passage of
small, lipid-soluble (lipophilic) molecules by passive diffusion while excluding ionized, protein-bound, and large
molecules (NR 546, neurobiology review). Highly ionized drugs and those strongly protein bound cross poorly.
This principle explains why lipophilic psychotropics such as fluoxetine and diazepam achieve robust central
concentrations.
Q4: Sertraline has an elimination half-life of approximately 26 hours. A patient begins taking
50 mg daily. Approximately how long will it take to reach steady-state plasma concentrations?
A. 26 hours
B. 2 days
C. 5 to 6 days *[CORRECT]*
D. 30 days
Correct Answer: C
Rationale: As a pharmacokinetic rule, steady state is reached after approximately four to five half-lives; for
sertraline this equals roughly 5 to 6 days of consistent dosing (NR 546 pharmacokinetics competency). A single
half-life represents only partial accumulation, and 30 days far exceeds the expected window. Recognizing
steady-state timing guides the PMHNP on when to assess efficacy and when serum levels, if applicable, should be
drawn.
Aligned with AACN Essentials of Master's Education and PMHNP Psychopharmacology Competencies 2
,NR 546 Advanced Pharmacology: Psychopharmacology - PMHNP Exam Prediction
Q5: Which cytochrome P450 enzyme is responsible for the metabolism of the largest
percentage of currently marketed medications, including many psychotropics such as
aripiprazole and quetiapine?
A. CYP2D6
B. CYP3A4 *[CORRECT]*
C. CYP1A2
D. CYP2C9
Correct Answer: B
Rationale: CYP3A4 metabolizes approximately 30 percent of marketed drugs and is the most abundant CYP
enzyme in the liver and gut wall. CYP2D6, CYP1A2, and CYP2C9 each metabolize smaller shares, although they
remain clinically important for specific agents such as risperidone (CYP2D6), clozapine and olanzapine
(CYP1A2), and phenytoin or warfarin (CYP2C9). Polypharmacy in psychiatric patients frequently involves
CYP3A4 competition.
Q6: Pharmacogenomic testing reveals that a patient with major depressive disorder is a
CYP2D6 poor metabolizer. The patient is prescribed nortriptyline. What is the most likely
clinical consequence?
A. Subtherapeutic plasma levels with treatment failure
B. Reduced risk of anticholinergic side effects
C. Accelerated clearance requiring a higher dose
D. Elevated plasma levels with increased risk of anticholinergic and cardiotoxic effects
*[CORRECT]*
Correct Answer: D
Rationale: CYP2D6 poor metabolizers have reduced enzymatic activity, so tricyclic antidepressants such as
nortriptyline accumulate, raising the risk of anticholinergic burden, orthostatic hypotension, and cardiac
conduction delay (CPIC pharmacogenomic guidance incorporated in NR 546). Options A and C describe
ultra-rapid metabolizers. Therapeutic drug monitoring with dose reduction is the appropriate response.
Q7: Escitalopram and citalopram are primarily metabolized by which enzyme, making poor
metabolizers candidates for lower maximum dosing per FDA guidance?
A. CYP2C19 *[CORRECT]*
B. CYP2D6
C. CYP2C9
D. CYP3A4
Correct Answer: A
Rationale: Citalopram and escitalopram are primarily metabolized by CYP2C19; the FDA recommends a lower
maximum dose, particularly in CYP2C19 poor metabolizers and in adults older than 60, because of QT
prolongation risk. CYP2D6 plays a minor secondary role, and CYP3A4 and CYP2C9 are not principal pathways.
Pharmacogenomic awareness supports individualized SSRI selection and dosing.
Aligned with AACN Essentials of Master's Education and PMHNP Psychopharmacology Competencies 3
, NR 546 Advanced Pharmacology: Psychopharmacology - PMHNP Exam Prediction
Q8: Which statement best describes the function of P-glycoprotein at the blood-brain barrier?
A. It actively transports lipophilic drugs out of the central nervous system back into the
systemic circulation *[CORRECT]*
B. It enhances passive diffusion of small molecules into the brain
C. It metabolizes psychotropic drugs within the endothelial cells of cerebral capillaries
D. It synthesizes the tight junction proteins that form the physical barrier
Correct Answer: A
Rationale: P-glycoprotein is an ATP-dependent efflux transporter expressed on the luminal surface of
blood-brain barrier endothelium; it pumps many substrates back into the circulation, limiting central exposure.
Inhibitors such as quinidine or cyclosporine increase brain penetration of P-glycoprotein substrates, while inducers
decrease it. This mechanism influences central effects of several antidepressants and other medications.
Q9: A 34-year-old woman with bipolar disorder who has been stable on carbamazepine reports
light bleeding between periods after starting an oral contraceptive. What pharmacokinetic
mechanism explains this interaction?
A. Carbamazepine inhibits CYP2C9 and raises estrogen levels
B. The oral contraceptive induces CYP3A4 and lowers carbamazepine levels
C. Carbamazepine displaces estrogen from albumin binding sites
D. Carbamazepine induces CYP3A4 and accelerates estrogen metabolism, lowering
contraceptive efficacy *[CORRECT]*
Correct Answer: D
Rationale: Carbamazepine is a potent CYP3A4 inducer and also induces its own metabolism (autoinduction);
induction of estrogen metabolism can produce breakthrough bleeding and contraceptive failure. Affected patients
should be counseled on barrier methods or adjusted hormonal strategies per NR 546 drug-interaction content.
Options A, B, and C reverse or misstate the induction and inhibition mechanisms.
Q10: A patient stabilized on warfarin for atrial fibrillation is prescribed divalproex sodium.
Which mechanism is most likely to elevate the international normalized ratio?
A. Displacement of warfarin from plasma protein binding sites by valproate
*[CORRECT]*
B. Induction of hepatic warfarin metabolism by valproate
C. Valproate-mediated increased platelet production masking anticoagulation
D. Reduced absorption of warfarin from the gastrointestinal tract
Correct Answer: A
Rationale: Valproate is highly protein bound and can displace warfarin from albumin, transiently increasing free
warfarin concentration and anticoagulant effect; additive antiplatelet effects may further raise bleeding risk (NR
546, protein-binding interactions). Induction would lower warfarin levels rather than raise them. The PMHNP
should coordinate INR monitoring with the primary prescriber when combining these agents.
Aligned with AACN Essentials of Master's Education and PMHNP Psychopharmacology Competencies 4
PREDICTION 175 QUESTIONS (ALL CORRECT
ANSWERS, ALREADY GRADED A)
Advanced Pharmacology: Psychopharmacology for the Psychiatric-Mental Health Nurse Practitioner
(PMHNP)
Chamberlain University Course Alignment | Graduate Nursing and Advanced Practice
Psychiatric-Mental Health Education
All Correct Answers Marked with Detailed Rationales | Cognitive Mix: 20% Recall - 50% Application - 30% Analysis |
75% Scenario Based, 25% Direct Knowledge
Section 1: Principles of Psychopharmacology
Q1: A nursing student is reviewing the four phases of pharmacokinetics as they apply to
psychotropic medications. Which term describes the movement of a drug from the systemic
circulation into target tissues such as the brain, liver, and fat stores?
A. Absorption
B. Distribution *[CORRECT]*
C. Biotransformation
D. Excretion
Correct Answer: B
Rationale: Distribution is the movement of a drug from the bloodstream into tissues and is heavily influenced by
protein binding, lipid solubility, and regional blood flow (NR 546, Module 1: Pharmacokinetic Principles).
Absorption describes entry into the bloodstream from the administration site, while biotransformation
(metabolism) and excretion describe elimination processes. Understanding distribution is essential when
predicting central nervous system penetration of psychotropics.
Aligned with AACN Essentials of Master's Education and PMHNP Psychopharmacology Competencies 1
,NR 546 Advanced Pharmacology: Psychopharmacology - PMHNP Exam Prediction
Q2: Which statement accurately differentiates pharmacodynamics from pharmacokinetics?
A. Pharmacokinetics describes receptor binding and downstream second-messenger
activity
B. Pharmacodynamics describes the concentration of drug achieved in the cerebrospinal
fluid
C. Pharmacodynamics describes what a drug does to the body, including receptor affinity
and signal transduction *[CORRECT]*
D. Pharmacokinetics describes the relationship between dose and therapeutic response at
the receptor
Correct Answer: C
Rationale: Pharmacodynamics refers to the biochemical and physiologic effects of drugs and their mechanisms
of action, including receptor binding, enzyme inhibition, and second-messenger signaling. Pharmacokinetics, in
contrast, describes what the body does to the drug across absorption, distribution, metabolism, and excretion
(AACN Essentials, scientific foundation domain). Options A and D reverse the definitions, and option B describes
a pharmacokinetic measurement.
Q3: A newly developed antipsychotic is noted to cross the blood-brain barrier readily. Which
drug property best explains effective central nervous system penetration?
A. High ionization at physiologic pH
B. Strong binding to plasma albumin
C. High molecular weight with poor solubility
D. High lipid solubility at physiologic pH *[CORRECT]*
Correct Answer: D
Rationale: The blood-brain barrier consists of tight junctions and astrocytic foot processes that permit passage of
small, lipid-soluble (lipophilic) molecules by passive diffusion while excluding ionized, protein-bound, and large
molecules (NR 546, neurobiology review). Highly ionized drugs and those strongly protein bound cross poorly.
This principle explains why lipophilic psychotropics such as fluoxetine and diazepam achieve robust central
concentrations.
Q4: Sertraline has an elimination half-life of approximately 26 hours. A patient begins taking
50 mg daily. Approximately how long will it take to reach steady-state plasma concentrations?
A. 26 hours
B. 2 days
C. 5 to 6 days *[CORRECT]*
D. 30 days
Correct Answer: C
Rationale: As a pharmacokinetic rule, steady state is reached after approximately four to five half-lives; for
sertraline this equals roughly 5 to 6 days of consistent dosing (NR 546 pharmacokinetics competency). A single
half-life represents only partial accumulation, and 30 days far exceeds the expected window. Recognizing
steady-state timing guides the PMHNP on when to assess efficacy and when serum levels, if applicable, should be
drawn.
Aligned with AACN Essentials of Master's Education and PMHNP Psychopharmacology Competencies 2
,NR 546 Advanced Pharmacology: Psychopharmacology - PMHNP Exam Prediction
Q5: Which cytochrome P450 enzyme is responsible for the metabolism of the largest
percentage of currently marketed medications, including many psychotropics such as
aripiprazole and quetiapine?
A. CYP2D6
B. CYP3A4 *[CORRECT]*
C. CYP1A2
D. CYP2C9
Correct Answer: B
Rationale: CYP3A4 metabolizes approximately 30 percent of marketed drugs and is the most abundant CYP
enzyme in the liver and gut wall. CYP2D6, CYP1A2, and CYP2C9 each metabolize smaller shares, although they
remain clinically important for specific agents such as risperidone (CYP2D6), clozapine and olanzapine
(CYP1A2), and phenytoin or warfarin (CYP2C9). Polypharmacy in psychiatric patients frequently involves
CYP3A4 competition.
Q6: Pharmacogenomic testing reveals that a patient with major depressive disorder is a
CYP2D6 poor metabolizer. The patient is prescribed nortriptyline. What is the most likely
clinical consequence?
A. Subtherapeutic plasma levels with treatment failure
B. Reduced risk of anticholinergic side effects
C. Accelerated clearance requiring a higher dose
D. Elevated plasma levels with increased risk of anticholinergic and cardiotoxic effects
*[CORRECT]*
Correct Answer: D
Rationale: CYP2D6 poor metabolizers have reduced enzymatic activity, so tricyclic antidepressants such as
nortriptyline accumulate, raising the risk of anticholinergic burden, orthostatic hypotension, and cardiac
conduction delay (CPIC pharmacogenomic guidance incorporated in NR 546). Options A and C describe
ultra-rapid metabolizers. Therapeutic drug monitoring with dose reduction is the appropriate response.
Q7: Escitalopram and citalopram are primarily metabolized by which enzyme, making poor
metabolizers candidates for lower maximum dosing per FDA guidance?
A. CYP2C19 *[CORRECT]*
B. CYP2D6
C. CYP2C9
D. CYP3A4
Correct Answer: A
Rationale: Citalopram and escitalopram are primarily metabolized by CYP2C19; the FDA recommends a lower
maximum dose, particularly in CYP2C19 poor metabolizers and in adults older than 60, because of QT
prolongation risk. CYP2D6 plays a minor secondary role, and CYP3A4 and CYP2C9 are not principal pathways.
Pharmacogenomic awareness supports individualized SSRI selection and dosing.
Aligned with AACN Essentials of Master's Education and PMHNP Psychopharmacology Competencies 3
, NR 546 Advanced Pharmacology: Psychopharmacology - PMHNP Exam Prediction
Q8: Which statement best describes the function of P-glycoprotein at the blood-brain barrier?
A. It actively transports lipophilic drugs out of the central nervous system back into the
systemic circulation *[CORRECT]*
B. It enhances passive diffusion of small molecules into the brain
C. It metabolizes psychotropic drugs within the endothelial cells of cerebral capillaries
D. It synthesizes the tight junction proteins that form the physical barrier
Correct Answer: A
Rationale: P-glycoprotein is an ATP-dependent efflux transporter expressed on the luminal surface of
blood-brain barrier endothelium; it pumps many substrates back into the circulation, limiting central exposure.
Inhibitors such as quinidine or cyclosporine increase brain penetration of P-glycoprotein substrates, while inducers
decrease it. This mechanism influences central effects of several antidepressants and other medications.
Q9: A 34-year-old woman with bipolar disorder who has been stable on carbamazepine reports
light bleeding between periods after starting an oral contraceptive. What pharmacokinetic
mechanism explains this interaction?
A. Carbamazepine inhibits CYP2C9 and raises estrogen levels
B. The oral contraceptive induces CYP3A4 and lowers carbamazepine levels
C. Carbamazepine displaces estrogen from albumin binding sites
D. Carbamazepine induces CYP3A4 and accelerates estrogen metabolism, lowering
contraceptive efficacy *[CORRECT]*
Correct Answer: D
Rationale: Carbamazepine is a potent CYP3A4 inducer and also induces its own metabolism (autoinduction);
induction of estrogen metabolism can produce breakthrough bleeding and contraceptive failure. Affected patients
should be counseled on barrier methods or adjusted hormonal strategies per NR 546 drug-interaction content.
Options A, B, and C reverse or misstate the induction and inhibition mechanisms.
Q10: A patient stabilized on warfarin for atrial fibrillation is prescribed divalproex sodium.
Which mechanism is most likely to elevate the international normalized ratio?
A. Displacement of warfarin from plasma protein binding sites by valproate
*[CORRECT]*
B. Induction of hepatic warfarin metabolism by valproate
C. Valproate-mediated increased platelet production masking anticoagulation
D. Reduced absorption of warfarin from the gastrointestinal tract
Correct Answer: A
Rationale: Valproate is highly protein bound and can displace warfarin from albumin, transiently increasing free
warfarin concentration and anticoagulant effect; additive antiplatelet effects may further raise bleeding risk (NR
546, protein-binding interactions). Induction would lower warfarin levels rather than raise them. The PMHNP
should coordinate INR monitoring with the primary prescriber when combining these agents.
Aligned with AACN Essentials of Master's Education and PMHNP Psychopharmacology Competencies 4
